Interferon beta in multiple sclerosis: predicting response at an early stage.
Killestein
Joep
J
Department of Neurology, VU Medical Centre Amsterdam, The Netherlands.
Hartung
Hans-Peter
HP
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000906:Antibodies / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000276:immunology / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology; D009460:Neurologic Examination / Q000187:drug effects; D009500:Neutralization Tests; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000906:Antibodies; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta